OMNIAB, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.48 USD | +1.13% |
|
-4.07% | -27.39% |
| 03-25 | OmniAb Insider Bought Shares Worth $1,167,750, According to a Recent SEC Filing | MT |
| 03-21 | Sector Update: Health Care Stocks Gain Pre-Bell Thursday | MT |
| Sales 2024 * | 31.75M 2.54B | Sales 2025 * | 57.08M 4.57B | Capitalization | 527M 42.18B |
|---|---|---|---|---|---|
| Net income 2024 * | -60M -4.8B | Net income 2025 * | -41M -3.28B | EV / Sales 2024 * | 16.6 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 9.23 x |
| P/E ratio 2024 * |
-7.63
x | P/E ratio 2025 * |
-11.5
x | Employees | 106 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.6% |
More Fundamentals
* Assessed data
More news
Latest transcript on OmniAb, Inc.
More recommendations
More press releases
| 1 day | +1.13% | ||
| 1 week | -4.07% | ||
| Current month | -17.34% | ||
| 1 month | -16.88% | ||
| 3 months | -27.63% | ||
| Current year | -27.39% |
1 week
4.40
4.81
1 month
4.405.54
Current year
4.406.72
1 year
3.146.72
3 years
1.9110.50
5 years
1.9110.50
10 years
1.9110.50
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.07% | 27 M€ | -5.03% | - | |
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 9 M€ | +6.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 4.48 | +1.13% | 598,745 |
| 25/04/24 | 4.43 | -2.85% | 586,988 |
| 24/04/24 | 4.56 | -1.72% | 557,392 |
| 23/04/24 | 4.64 | -0.85% | 367,629 |
| 22/04/24 | 4.68 | +0.21% | 301,000 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Companyâs OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
Calendar
08/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.48
USD
Average target price
10
USD
Spread / Average Target
+123.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.39% | 527M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- OABI Stock
